
Alphabet unit Verily has taken part in an oversubscribed series B round that will fund Mammoth Biosciences' expansion from diagnostics to gene editing and drug development.
Waters Corporation reinvested in the protein characterisation technology producer through an oversubscribed round that will fund innovation and expansion.
Wuxi AppTec and Alphabet are in line to exit the molecule-discovery software provider, which has set the range for its initial public offering.
AbbVie Ventures took a board seat through its contribution to the round, closed as the inflammatory disease therapy developer emerged from stealth.
Merck Group spinoff iOnctura will put the $18.7m it raised in the M Ventures-backed round into a clinical trial for its solid tumour therapy.
Scott Brun, who headed AbbVie Ventures until last April, has taken on an R&D advisory role at pharmaceutical company Horizon Therapeutics.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
3M, CareFirst BlueCross BlueShield, Lafayette General Health, OSF Healthcare and ProMedica all invested as the healthcare technology provider closed an $11.1m round.
Sanofi is in line for an exit as Revolution Medicines files for a $100m initial public offering on the Nasdaq Global Market.
University Hospital Tübingen's liver disease treatment spinout HepaRegenix has raised $21.6m in all following a series B round that featured Novo and Boehringer Ingelheim.